NRIX vs DSGN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NRIX Captures Institutional Edge (3โ1 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nurix Therapeutics, Inc. Common stock (NRIX) driven by superior Valuation, Growth & Margin, Options & Structure while DSGN counters with relative strength in Momentum & Technical. Fundamentally, NRIX trades at N/M Forward P/E with 41.3% operating margin (+8426.3% YoY revenue) versus DSGN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, NRIX sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro) against DSGN sits in BREAKDOWN (13th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NRIX Revenue | DSGN Revenue | NRIX Op. Margin | DSGN Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $30M | N/A | -71.5% | N/A | NRIX |
| FY2020 | $20M | $0M | -364.7% | -3685.8% | NRIX |
| FY2021 | $30M | N/A | -396.3% | N/A | NRIX |
| FY2022 | $40M | N/A | -476.0% | N/A | NRIX |
| FY2023 | $80M | N/A | -201.4% | N/A | NRIX |
| FY2024 | $50M | N/A | -390.5% | N/A | NRIX |
| FY2025 | $80M | N/A | -340.2% | N/A | NRIX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NRIX | DSGN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.7B | $677.5M | Larger Scale | NRIX |
| Trailing P/E Ratio Valuation | 6.4x | N/M | Lower Multiple | NRIX |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +8426.3% | +0.0% | Higher Growth | NRIX |
| Operating Margin (TTM) Profitability | 41.3% | 0.0% | Higher Margin | NRIX |
| Net Profit Margin Profitability | 42.0% | 0.0% | Higher Margin | NRIX |
| Return on Equity (ROE) Capital Efficiency | 44.0% | -36.9% | Higher ROE | NRIX |
| 52-Week Range Position Momentum | 18% ($12โ$28) | 30% ($7โ$17) | Stronger Trend | DSGN |
| Beta / 30D Volatility Risk Regime | 0.94ฮฒ ยท 141% Vol | 1.32ฮฒ ยท 61% Vol | Lower Realized Risk | DSGN |
| Unified Institutional Score Composite Signal | 52.9 / 100 (HOLD) | 49.8 / 100 (HOLD) | Higher Composite | NRIX |